Hemostemix Inc V.HEM

Holding long

[Pimpovish]

More upside than down side now especially at 22 cents. I think investors deserve greater clarity. I still see big risk/reward but the messaging around the lawsuit and debenture needs to be better articulated.

[Walterthedog]

All Thomas needed to say at the agm was that we expect phase 2 results in 2 months and this should start to open doors for financing and create interest in the stock. Instead he was talking about how they were looking for primarily safety and to a lesser degree efficacy. When I asked about whether or not we needed anything from Aspire, he went into the details of source data verification. I

[Pimpovish]

Good post. Thomas needs to clarify in an easy to understand and transparent manner the status of the data from Aspire as well as the effect the lawsuit has on corporate impairment. Investors are selling for 2 reasons: constant delays in clinical results and a general lack of transparency. I would like to think its a communication issue but obviously investors are speaking loudly through the heavy

[Walterthedog]

The questions and rumors that we still need data from Aspire have been circulating on CEO.ca and elsewhere for a while now and if we had what we needed he could have dispelled that bad info easily but has not. and even when i directly questioned him about it in the agm, i got an answer describing the source data verification procedure so I'm fully expecting in August to hear that we can not